Robotic Blood-Drawing Device On Track for Commercialization

Vitestro, a company developing robotic solutions for autonomous blood drawing, has raised $22 million to accelerate commercialization of its robotic blood drawing device. 

The latest round was co-led by return investor Sonder Capital and new investor NYBC Ventures, with participation from Invest-NL, the European Innovation Council Fund and existing private investors.

The round brings the company’s total funding to $50 million.

Vitestro said the money will be used to ramp up its commercialization plans in Europe and its organizational expansion into the U.S. market. The funds will also be used to develop additional product features for the device as the team prepares for rollout.

“Early feedback from hospitals, staff and patients has been overwhelmingly positive, and we are eager to quickly expand our reach and impact globally,” said Toon Overbeeke, Vitestro’s CEO. 

The company’s autonomous solution uses AI, ultrasound-guided imaging technology and robotic needle insertion to enable accurate, autonomous blood draws.

Vitestro said it is on track to receive approval for its device by the end of this year, with several of its devices scheduled for deployment at several European hospitals starting at the end of this year.  

"Vitestro’s revolutionary device is perfectly positioned to improve patient care and streamline operations for a medical laboratory market in crisis,” said Fred Moll, managing partner at Sonder Capital. “As turnover and departures accelerate, staff are overwhelmed and labs are challenged to deliver timely test results and satisfactory care. We are excited by Vitestro’s progress and believe they will modernize the blood draw experience.”

Related:Nvidia-Backed Dental Surgery Robot Gets $20M Funding Boost